Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ChromaDex Corporation (CDXC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7600-0.0500 (-1.78%)
At close: 04:00PM EST
2.7600 0.00 (0.00%)
After hours: 06:27PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close2.8100
Open2.8500
Bid2.7100 x 3100
Ask3.0600 x 800
Day's Range2.7300 - 3.0800
52 Week Range2.5100 - 23.6600
Volume1,383,822
Avg. Volume353,364
Market Cap188.485M
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CDXC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ChromaDex Corporation
    CDMO: Lowering target price to $20.00AVID BIOSERVICES INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Business Wire

    ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

    LOS ANGELES, January 25, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or "NR") ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation. The study investigated the anti-inflammatory effects of ChromaDex’s proprietary NR ingredient in monocytes (a type of white blood cell) extracted from two groups: young, healthy subjects and patients diagnosed with system

  • Business Wire

    ChromaDex and Designs for Health Partner for New Product Development on Niagen®

    LOS ANGELES, January 20, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be available exclusively through the company’s exte

  • Business Wire

    ChromaDex Corporation Reports Third Quarter 2021 Financial Results

    LOS ANGELES, November 03, 2021--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021.

Advertisement
Advertisement